• Total product sales of €64.0 million
    • In-line with expectations; full-year guidance of €135 -150 million reaffirmed
  • Solid cash position of €121.5 million as of end June 2026
    • Reflects disciplined cash management and proceeds from the recent reserved offering1
    • Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond
  • Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2  
    • Pfizer remains optimistic about obtaining registration for the vaccine candidate3